Purchase Order 75N95024P00589
Award Date
12/10/24
Potential Completion Date
12/9/25
Potential Value
$113K
Federal Agency
National Institute on Drug Abuse
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Human Genome Research Institute awarded a $15,000 purchase order to Illumina, Inc. to provide DRAGEN CS LVL 1 LICENSE THROUGHPUT OF 100,000GB under contract number E21C6L5011010032. The one-year contract, which runs from July 2025 through July 2026, calls for Illumina to deliver genomic sequencing software licensing and throughput on a firm fixed price basis, to be billed quarterly in arrears. As the prime...
The Department of Health and Human Services National Institutes of Health National Human Genome Research Institute awarded a firm fixed price purchase order valued at twenty thousand two hundred ninety-eight dollars and ninety-nine cents ($20,298.99) to Illumina, Inc. to provide a one-year license for the DRAGEN CS Level 1 throughput of one hundred thousand gigabytes. The license will be delivered under a thirteen point six month period running from May seventh, two thousand twenty-one through...
This firm fixed price purchase order was awarded to Illumina, Inc. by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), for the deployment of two Illumina DRAGEN Server v4 systems and associated licenses. The total ceiling value of the contract is $200,500.00, with a period of performance through October 26, 2025. The original solicitation indicates that the NCI requires the DRAGEN processors to support its Whole Genome and Whole Exome Data Processing...
This federal contract award, valued at $15,000.00, was issued by the National Human Genome Research Institute (NHGRI) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract is for a DRAGEN CS Level 1 License with a throughput of 100,000GB, with a period of performance from July 25, 2024 to July 24, 2025. The contract is a firm fixed price purchase order and does not have a set-aside designation. Illumina has previously received prime federal...
This is a firm fixed price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis products. The $82,507.48 contract has no set-aside designation and does not appear to be associated with a larger contracting vehicle. Under this award, Illumina will provide NIDA with various sequencing systems, reagents, consumables, and related services to support genomic research and diagnostics....
This is a $78,707.44 firm fixed price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Illumina, Inc. The contract does not have a set-aside designation. Illumina, a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis, is providing various sequencing systems, reagents, consumables, and other support services to NIDA under this award. Illumina has previously received...
This is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of genetic sequencing and genomic analysis instruments and consumables. The award, valued at $12,524.80, is for the delivery of Illumina sequencing systems and related products to support NIDA's research and diagnostics needs. This award is not associated with a set-aside program. Illumina has received multiple...
This is a firm fixed price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Illumina, Inc. for maintenance support services on NIDA's existing Illumina sequencing systems. The contract has a ceiling value of $144,898.72 and an ultimate completion date of December 4, 2017. This purchase order is not associated with a set-aside program. Illumina, a manufacturer of sequencing and analysis products, has...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $38,362.17 firm fixed price purchase order to Illumina, Inc. on December 14, 2018 for goods and services to be delivered by December 16, 2019. The place of performance is Bethesda, Maryland. Illumina is a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis. No set-aside provision was used for this award to support the National...
This is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Illumina, Inc. The $292,500.00 contract is for the provision of Illumina sequencing systems, reagents, and associated products and services to support genomic sequencing and analysis. Illumina is an experienced provider of sequencing and genomic analysis technologies to federal agencies, having previously supported work at the NIH, Centers for...